

Original articles

Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series



Regiane Saraiva de Souza Melo Alencar^{a,b}, Claudia P. Oliveira^{b,c}, Aline Lopes Chagas^{a,b}, Leonardo Gomes da Fonseca^{a,b}, Claudia Maccali^{a,b}, Lisa Rodrigues da Cunha Saud^{a,b}, Mariana Pinheiro Xerfan^{a,b}, Jose Tadeu Stefano^{b,c}, Paulo Herman^d, Luiz Augusto Carneiro D'Albuquerque^e, Venâncio Avancini Ferreira Alves^{b,f}, Flair Jose Carrilho^{b,c,*}

^a Instituto do Câncer do Estado de São Paulo, São Paulo, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

^b São Paulo Clínicas Liver Cancer Group, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

^c Laboratório de Gastroenterologia Clínica e Experimental (LIM-07), Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

^d Digestive Surgery Division, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

^e Liver and Digestive Organ Transplantation Unit, Department of Gastroenterology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

^f Department of Pathology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

H I G H L I G H T S

- Obesity and its related complications are rapidly changing the epidemiology of many types of cancer, including HCC. As a result of this dynamic epidemiology, NAFLD and NASH-related HCC have risen – more rapidly than HCV, HBV, and other HCC's causes.
- The evaluation of HCC development, the role of screening, treatment, and outcomes on HCC-NAFLD patients is still controversial and not well described.
- Metabolic risk factors for NAFLD were present in the majority of the patients, even though a small percentage were in HCC screening programs before.
- Cumulative survival at the end of the first year was 72%, second year 52%, and fifth-year 32%. The independent factors associated with shorter general survival were BCLC C-D, and the size of the largest nodule > 42 mm.

A R T I C L E I N F O

Keywords:

Hepatocellular carcinoma
Non-alcoholic fatty liver disease
HCC screening program
Treatment
Overall survival

A B S T R A C T

Objective: The aim of the present study was to evaluate the clinical features, Hepatocellular Carcinoma (HCC) screening, treatment modalities, and Overall Survival (OS) in a series of Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma (NAFLD-HCC) Brazilian patients.

Methods: This was a cross-sectional study at the Instituto do Câncer do Estado de São Paulo, at the Faculdade de Medicina da Universidade de São Paulo with the approval of the local research ethics committee. NAFLD patients with HCC diagnosed, from May 2010 to May 2019, were included.

Results: A total of 131 patients were included. Risk factors for NAFLD were present in 94.7% of the patients. Only 29% of patients were in the HCC screening program before diagnosis. HCC treatment was performed in 84.7% of patients. Cumulative survival at the end of the first year was 72%, second-year 52%, and fifth-year 32%. HCC screening before diagnosis was not significantly associated with higher cumulative survival. The independent factors associated with shorter general survival were BCLC C-D, $p < 0.001$, and the size of the largest nodule > 42 mm, $p = 0.039$.

Conclusions: Although the efficacy of screening in our population regarding overall survival was hampered due to the sample size (29% had screening), BCLC stages C-D and the size of the largest nodule larger than 42 mm were identified as independent factors of worse prognosis.

*Corresponding author.

E-mail address: fjcarri@usp.br (F.J. Carrilho).

<https://doi.org/10.1016/j.clinsp.2022.100097>

Received 7 March 2022; Revised 30 June 2022; Accepted 26 July 2022

Introduction

Hepatocellular Carcinoma (HCC) is the most common primary malignant tumor of the liver and one of the most prevalent neoplasms worldwide.¹ Non-Alcoholic Fatty Liver Disease (NAFLD) represents a spectrum of metabolic fatty liver disorders, in which the hallmark remains upon the excessive fat deposition into the hepatic parenchyma.^{2–4} The pathologic spectrum of NAFLD ranges from simple steatosis to Non-Alcoholic Steatohepatitis (NASH), advanced fibrosis, and cirrhosis, leading to an increasing risk of progression to end-stage liver disease and HCC.^{5,6} Recently, a consensus of international experts, including one of us (CPO), proposed that the acronym of the disease be changed from NAFLD to fatty liver disease associated with metabolic dysfunction or “MAFLD” (“Metabolic dysfunction – associated fatty liver disease”).⁷ The diagnostic criteria for MAFLD are more comprehensive and simpler, and independent of other liver diseases, including alcoholic disease. The criteria used are based on evidence of hepatic steatosis in histology (biopsy), on imaging tests or confirmed by blood biomarkers, in association with at least one of the following three criteria: overweight/obesity, presence of Type 2 Diabetes Mellitus (T2DM) or evidence of metabolic dysregulation. Although the authors fully endorse the use of the new term, retrospective studies still use NAFLD/NASH because exclusion of the use of alcohol and other etiologies had been defined early in the design of the study.

The pandemic of obesity and its related complications is rapidly changing the epidemiology of many types of cancer, including HCC.⁸ As a result of this dynamic epidemiology, NAFLD and NASH-related HCC have risen – more rapidly than HCV, HBV, and other HCC’s causes.^{9–13} A recent American study, from the Medicare database, revealed that: among all patients with HCC, NAFLD was the most common underlying cause of this type of neoplasm.^{14,15} In fact, approximately 2 billion adults are obese or overweight around the world^{15,16} and an estimated 415 million people have diabetes, both factors standing as a significant role in the rise of NAFLD prevalence, especially in the occidental countries.^{17–19} Additionally, T2DM has become a daunting epidemic in the Asia Pacific region, with some experts estimating a 150% increase in diabetes rate between 2000 and 2035, emphasizing the increasing burden of the disease in the oriental regions of the world. This evidence also shows that the definition of obesity is not uniform across the globe and individuals in the Eastern tend to have a lower Body Mass Index (BMI) than the rest of the world. However, even in Asia-Pacific Region, recent studies have also demonstrated a growing problem with both obese NAFLD as well as lean NAFLD and lean NASH.^{20,21}

Published series indicate that patients with NAFLD-HCC generally have a worse prognosis compared to HCC of other causes.^{22–26} Contributory factors include NAFLD-HCC being diagnosed at a more advanced stage of disease, hand-in-hand with either ineffective or absent surveillance, as well as NAFLD-HCC patients often being older with more comorbidities, limiting the use of curative treatments such as liver resection and liver transplantation.^{23–27} Current understanding of the pathogenesis underlying the development of HCC, especially in the absence of cirrhosis, is poorly understood. It is expected that by further understanding this, reliable non-invasive biomarkers will be developed which will allow effective screening and early diagnosis of HCC, particularly in the non-cirrhotic NAFLD population. It is also hoped that by understanding the pathogenesis better strategies to prevent the development of HCC from NAFLD may be fostered. More effective and better tolerated systemic therapies are also highly needed, given the majority of patients with NAFLD-HCC present at an advanced stage.

In real life, the evaluation of HCC development, the role of screening, treatment, and outcomes on HCC-NAFLD patients is still controversial and not well described. The aim of the present study was to evaluate the clinical features, HCC screening, treatment modalities, and Overall Survival (OS) in a series of NAFLD-HCC Brazilian patients.

Materials and methods

A Cross-sectional study was performed at the Instituto do Cancer do Estado de São Paulo (ICESP), Faculdade de Medicina da Universidade de São Paulo (FMUSP) with the approval of the competent research ethics committees. The authors included all patients with HCC diagnosed according to the American Association for the Study of Liver Diseases (AASLD) and European Association for the Study of the Liver (EASL) Criteria,^{28,29} between May 2010 until May 2019, with a diagnosis of NAFLD. The authors excluded patients with missing or incomplete data, presence of other causes overlapped with NAFLD, and presence of other tumors which might compromise HCC treatment response or patient survival. All data were systematically tabulated on the Red Cap platform® and statistical analysis was completed afterward.

Patient records were reviewed by a single investigator and the following variables were assessed:

- Analysis of demographic and clinical variables:** Age; Sex; Etiology: NAFLD; Presence of risk factors for NAFLD: T2DM: fasting glycemia > 126 Glucose intolerance: Glycemia between 100 and 125 mg/dL; Systemic Hypertension: Systolic Pressure > 140 mmHg and/or Diastolic Pressure > 90 mmHg, Dyslipidemia (DLP): LDL Cholesterol > 130 mg/dL and/or triglycerides > 150 mg/dL; Obesity: BMI > 30; Overweight: BMI between 25 and 30. Ascites: presence/absence; Liver Encephalopathy: presence/absence; Child-Pugh Score: Values: A-5 and 6; B-7 to 9; C-10 to 15; MELD score; Performance Status scale: ECOG 0 to 4.
- Laboratories values** (alpha-fetoprotein, liver functions tests);
- Evaluation of HCC: Diagnosis:** date, diagnostic method: imaging/biopsy; number and size of nodules; Milan Criteria; Barcelona Clinic Liver Cancer (BCLC) staging; Treatment options: Transarterial Chemoembolization (TACE), Radiofrequency Ablation (RFA), Surgical Resection, Sorafenib, Liver Transplant; Response to Treatment: Evaluation by mRECIST: ³⁰ Complete Response (CR), Partial Response (PR), Progressive Disease (PD), Stable Disease (SD);
- Clinical evolution:** Date of last follow-up or date of death.

The authors included patients with NAFLD because this was a retrospective study and because the current definition of MAFLD is not yet fully accepted worldwide and the authors excluded all patients with alcohol intake higher than 30 g/day. The authors defined NAFLD as if all other known etiologies of liver disease could be ruled out, and/or if consistent present or past histological or ultrasonography features of fatty liver and alcohol intake of less than 30 g/day. In the patients without risk factors for NAFLD or absence of suggestive image, biopsy was performed.

The diagnosis of cirrhosis was based either on histology or on clinical, ultrasound, endoscopic, and/or laboratory assessment. All patients were assessed for the presence/absence of portal hypertension, which the authors defined indirectly as the presence of esophageal varices, splenomegaly, and platelets $\leq 100,000 \text{ mm}^3$.

Presence/absence of cirrhosis complications (ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis) before or at diagnosis of HCC and presence/absence of HCC symptoms at diagnosis of HCC (pain, hyporexia, weight loss).

The authors evaluated the participation of patients in an HCC screening program: ultrasound and/or alpha-fetoprotein and its frequency: every 3-months; every 6-months, annually.

Statistical analysis

Continuous variables are expressed as mean \pm standard deviation, and categorical variables are expressed as the number of cases and proportions. A univariate Cox regression was performed to understand the crude effect of HCC screening and treatment in the OS. Two Models

Table 1
Sociodemographic, clinical and NAFLD risk factors characteristics of patients evaluated in the study.

	n or mean	% or \pm SD
Male gender	79	60.3%
Age	65	\pm 9.7
Race		
Caucasian	106	80.9%
Asian/Yellow	18	13.7%
Other	5	5.8%
History of tobacco consumption	59	45.0%
History of alcohol consumption (<30 g/day)	32	24.4%
BMI	28.7	\pm 5.7
NAFLD Risk factors	124	94.7%
Diabetes	85	67.5%
Glucose Intolerance	9	7.1%
Systemic Hypertension	96	76.2%
Dyslipidaemia	50	39.7%
Hyperuricemia	4	3.2%
Obesity (BMI > 30)	50	39.7%
Overweight (BMI 25-29.9)	49	38.9%
Total of risk factors	2.6	\pm 1.1
Aetiology of liver disease		
NASH	131	100%

including HCC screening and HCC treatment including other explanatory variables were considered to obtain an adjusted hazard ratio. Backward elimination was used to seek a better fit. Statistical analyses were carried out using IBM SPSS Statistics v. 26.0 (SPSS Inc., Chicago, Illinois, USA) and R packages (R Core Team, Vienna, Austria).³¹

Results

A total of 131 patients were included, 60.3% male, mean age 65 ± 9.7 years old, mostly Caucasian, without tobacco consumption history (55%), BMI 28.7 ± 5 . All sociodemographic, clinical, and NAFLD risk factors are presented in Table 1.

Table 2 shows the cirrhosis complications and laboratorial features of the patients. Cirrhosis was diagnosed in 90.8% of patients; Portal Hypertension in 72.5%. Clinical evidence of complications was observed in 51.3% before the diagnosis of HCC and 38.2% at the diagnosis of HCC. Child-Pugh A was observed in 51.9% of cases and the mean Meld score was 11.1 (± 4.2). The results of laboratory tests are also shown in Table 3.

The presence of risk factors was identified in 94.6% of patients: systemic hypertension (76.2%); T2DM (67.5%); DLP and obesity (39.7%); overweight (38.9%); glucose intolerance (7.1%) and hyperuricemia (3.2%).

Only 29% of patients were in the HCC screening program before diagnosis, with ultrasound and alpha-fetoprotein performed every 6 months.

Regarding the diagnostic method of HCC, 85.5% was done by imaging: CT scan in 87%, biopsy in 13.7%. Alpha-fetoprotein (ng/mL) showed a mean of $4,261.1\pm 13,948$ and a median of 12.4. In relation to the number of nodules of HCC at diagnosis, the authors found: 1 nodule: 57.3%; 2 nodules: 21.4%; 3 nodules: 7.6% and multifocal in 13.7% of the patients with the largest nodule diameter average of 54.5 mm.

According to Barcelona staging system (BCLC): 0: 5.3%; A: 42.7%; B: 25.2%; C: 16% and D: 10.7%.

HCC treatment was performed in 84.7% of patients TACE in 47.7%; RFA in 17.1%; Sorafenib in 16.2% whereas surgical resection was possible in 9.9% and Liver transplantation in 16.2%. More than one treatment was provided to 40.5% of patients.

At the last follow-up assessment (last visit or death), the authors checked the available images classified by mRECIST and observed that 80.9% of patients had control images: 42% had the progressive disease; 27.5% had complete response; 8.4% had partial response and

Table 2
Cirrhosis complications and HCC screening of patients evaluated in the study before HCC diagnosis.

	n or mean	% or \pm SD
Liver Cirrhosis	119	90.8%
Fibrosis Grade		
No Fibrosis	0	0.0%
I	2	16.7%
II	3	25.0%
III	7	58.3%
Analysis method		
NAFLD Score	3	25.0%
FIB4/APRI	2	16.7%
ARFI	0	0.0%
Percutaneous Biopsy	6	50.0%
NAFLD Score/FIB4/APRI	1	8.3%
Cirrhosis complications	61	51.3%
Ascites	49	80.3%
Variceal bleeding	28	45.9%
Spontaneous bacterial peritonitis	3	4.9%
Hepatic Encephalopathy	16	26.2%
Portal Hypertension	95	72.5%
HCC screening	38	29.0%
Screening interval		
Every 6 months	34	26.0%
Every 12 months	1	0.8%
Irregular	2	1.5%
Unknown	1	0.8%

3% stable disease. Nineteen percent did not present images since they were not submitted to any specific treatment for HCC (BCLC-D – best supportive care).

The main HCC-related features of patients evaluated in the study are presented in Table 4. HCC-related symptoms were observed in 30.5% of patients, including Abdominal pain and Weight loss in 75% and 67.5% of cases.

A total of 75 (57.3%) patients died, due to: liver failure: 42.3%; tumour progression: 28.8%; infections: 19%; cardiovascular

Table 3
Cirrhosis complications, laboratorial characteristics and Scores of patients evaluated in the study at HCC diagnosis.

	n or mean	% or \pm SD
Complications of Cirrhosis	50	38.2%
Ascites	46	92.0%
Variceal bleeding	3	6%
Encephalopathy	10	20.0%
Hepatorenal Syndrome	2	4.0%
Child-Pugh		
A	68	51.9%
B	42	32.1%
C	9	6.9%
Child-Pugh score	6.6	\pm 1.7
Meld score	11.1	\pm 4.2
Albumin (g/dL)	3.7	\pm 0.6
Creatinine (mg/dL)	0.99	\pm 0.65
Sodium (mEq/L)	139.6	\pm 4.3
Total bilirubin (mg/dL)	1.70	\pm 2.36
AST (Aspartate Aminotransferase) [U/L]	61.6	\pm 57.0
AST - Reference Value	34.6	\pm 2.9
ALT (Alanine Aminotransferase) [U/L]	48.2	\pm 62.3
ALT - Reference Value	37.1	\pm 5.1
GGT (Gamma-glutamyltransferase) [U/L]	218.9	\pm 264.5
GGT - Reference Value	51.2	\pm 12.4
Glucose (mg/dL)	137.4	\pm 98.5
Glycated haemoglobin (%)	6.7	\pm 1.8
Total cholesterol (mg/dL)	160.8	\pm 45.3
HDL (mg/dL)	45.0	\pm 19.1
LDL (mg/dL)	93.6	\pm 41.9
Triglycerides (mg/dL)	102.6	\pm 51.4
Platelets (thousand/mm³)	142.4	\pm 98.3
INR	2.00	\pm 8.34

Table 4
HCC characteristics of patients evaluated in the study

	n or mean	% or ±SD
HCC symptoms	40	30.5%
Weight loss	27	67.5%
Anorexia	7	17.5%
Abdominal pain	30	75.0%
Asthenia	19	47.5%
Number of nodules		
1	75	57.3%
2	28	21.4%
3	10	7.6%
Multifocal	18	13.7%
Diameter of largest nodule	54.5	±40.7
Milan Criteria	53	40.5
Alpha-fetoprotein	4,261	±13,948
ECOG-PS		
0	73	55.7%
1	40	30.5%
≥2	18	13.8%
BCLC stage		
0	7	5.3%
A	56	42.7%
B	33	25.2%
C	21	16.0%
D	14	10.7%
Tumor thrombosis	19	14.5%
HCC Treatment	111	84.7%

causes: 2.7%; immediate postoperative of liver transplantation: 3.6%; other causes: 3.6%.

The mean follow-up was 2.17 (±1.9) years and the median was 1.41 years. Cumulative survival at the end of the first year was 72%, second-year 52%, and the fifth-year 32%. The OS function is presented in Figure 1.

HCC screening before diagnosis was not significantly associated with higher cumulative survival in a simple Cox regression: Hazard Ratio (HR) 0.451 (95% CI 0.194 to 1.048), $p = 0.064$. After adjustment HR HCC screening before diagnosis remained non-significant resulting in $HR = 0.742$ (95% CI 0.384 to 1.436). The independent factors associated with shorter OS were BCLC C-D with $HR = 7.193$ (95% CI 3.662 to 14.129), $p < 0.001$, and the size of the largest nodule > 42 mm with $HR = 1.957$ (95% CI 1.035 to 3.699), $p = 0.039$. The gender of the patients and complications of cirrhosis at HCC diagnosis had no effect on cumulative survival. Figure 2 shows differences in cumulative survival before (a) and after adjustment (b) and Figures 3 and 4 show the adjusted effect in cumulative survival of BCLC at diagnosis and size of the largest nodule.

In the same way, the effect of treatment of HCC was strongly associated with longer survival in the univariate analysis with $HR = 0.225$ (95% CI 0.096 to 0.531), $p < 0.001$. However, in the multiple Cox regression HCC treatment loses its effect resulting in a $HR = 0.472$ (95% CI 0.188 to 1.185), $p = 0.110$. BCLC-B, $p = 0.008$ and C-D, $p < 0.001$ and the size of the largest nodule > 42 mm, $p = 0.002$ remain statistically significant. Figures 6 and 7 show adjusted effect of HCC treatment on the BCLC and the size of the largest nodule.

Discussion

Recent evidence shows that NAFLD is becoming a major cause of HCC, with a steadily rising incidence compared to viral or alcohol-induced chronic hepatitis. HCC stands for the most severe and important complication of NAFLD and probably the most challenging in clinical practice.⁸ In medical literature, the authors have few population-based studies performed on the HCC-NAFLD population,³² and since de the 90s, it has been seen that most of the




Figure 1. Overall survival function in the set of evaluated individuals.




Figure 2. Overall survival function including crude effect (a) and adjusted effect (b) of HCC screening.




Figure 3. Overall survival function including the adjusted effect of Barcelona Clinic Liver Cancer Group stage at diagnosis.

studies which correlate HCC with NAFLD patients are based on secondary cohort studies, of both liver cancer management and liver transplant databases.^{33–35}

Specific data such as demographic profile, clinical presentations and the specific risk factor is still scarce on NAFLD-HCC patients, and at the same time very needed to support screening programs. Similarly,

evidence evaluating therapeutic response rates of HCC in patients with NAFLD/NASH, and their specific OS is lacking in our population and worldwide. The present study aims to collaborate on this matter, providing Real-World data in order to support health public policies for NAFLD/NASH-HCC group, and therefore reducing the rising mortality of this group of patients.




Figure 4. Overall survival function including adjusted effect of size of the largest nodule.




Figure 5. Overall survival function including crude effect (a) and adjusted effect (b) of HCC treatment.

The present study included a total of 131 individuals, and the authors described 60.3% of male patients, and 80.9% of Caucasian ethnicity declared. The mean age ranges from 65 ± 9.7 years old. The literature corroborates with this gender and mean-age data, and it is well known that HCC affects mostly adult men, with a greater incidence around 60–70 years.^{25,32,36-38}

NAFLD itself is related to being more common in men (42% for white males vs. 24% for white females) and the prevalence of NAFLD increases with age. With the rise in the incidence of NAFLD-HCC cases recently,

the contribution of NAFLD is underscored among the risk factors that induce HCC.³⁸

A Brazilian retrospective and observational study, published in 2020, using Brazil’s public database system (DataSUS) analyzed more than 28,000 cases of HCC with all etiologies included, which reported that most of the patients were men and diagnosed with a mean age of 59.7 years old.³⁷ And according to Globocan publications in 2019, HCC is the fifth most common cancer in men and the ninth most commonly occurring cancer in women.




Figure 6. Overall survival function including adjusted effect of Barcelona Clinic Liver Cancer Group stage in the HCC treatment.




Figure 7. Overall survival function including adjusted effect of size of the largest nodule in the HCC treatment.

In our studied population with HCC the risk factors for NAFLD were present in 94.6% of the patients: 76.2% with hypertension; 67.5% with T2DM; 39.7% with diagnosed obesity and 38.9% with overweight, accounting for a medium BMI in 28.7. DLP was present in 39.7% of these patients and Glucose intolerance in approximately 7.1%.

NAFLD increases the risk of liver, cardiovascular and all-cause mortality, and it is classically associated with metabolic disorders such as obesity, hypertension, DLP, insulin resistance, and T2DM.³⁹ Steatosis progresses to necroinflammation leading to hepatocarcinogenesis as a consequence of multiple parallel acting conditions such as insulin resistance, hyperinsulinemia, DLP, adipose tissue remodeling, oxidative/endoplasmic reticulum stress, altered immune system, genetic alterations, and dysbiosis in the gut microbiome.³⁸

Obesity and T2DM have a well-established, independent, and cumulative impact on the development of HCC. An English analysis from over 5.24 million patients in the Clinical Practice Research Datalink described that BMI was positively associated with liver cancer (HR = 1.19, 95% CI 1.12–1.27).³⁴ In 2010 an American population-based study evidence that NAFLD was the most common risk factor for the development of HCC in a six-year follow-up.³⁶

In the modern era with a sedentary lifestyle and unhealthy dietary habits, obesity is rapidly increasing and has been established as a risk factor for HCC.³⁶

Cirrhosis was present in 90.8% of our patients, being 51.9% designated with Child-Pugh A score. Our data is according to the literature findings. The prevalence of cirrhosis among NAFLD-HCC patients is described as being greater than 70%.³²

For the past 20 years, NAFLD has been proposed as the underlying cause of most cases of cryptogenic cirrhosis, and Cirrhosis itself remains one of the most important characterizations of NAFLD-HCC patients because it changes – not only from the diagnosis and clinical findings – but the whole prognosis, the clinical decompensations, the impact over HCC treatment response rates, the liver transplantation rates, and the final OS. Not to mention the quality of life that is greatly impacted by advanced fibrosis and cirrhotic patients worldwide.

Another finding of our study was that in 51.3% of patients there was a clinical presentation of liver decompensation before HCC diagnosis, with ascites being the most common complication accounted (80.3%). Weinmann et al. described the clinical features and outcomes of 1,119 HCC patients (all etiologies including NASH) treated over an 11-yr period and compared the findings for NASH-HCC with others. In this study liver function was preserved in NASH-HCC cases.²⁶

Despite evidence that NAFLD-associated HCC may arise in the absence of cirrhosis, is often diagnosed at advanced stages, current society guidelines provide limited guidance/recommendations addressing HCC surveillance in patients with NAFLD outside the context of established cirrhosis. There is reasonable epidemiological cohort data to recommend surveillance of patients with NASH-related cirrhosis based on the incidence of HCC in this specific population. However, programming an optimal screening strategy for the early detection of HCC in this population is not an easy task.

Both in Brazil and worldwide, the authors evidence that cost-effective screening programs are currently hampered by limited tools able to stratify the risk of HCC in the NAFLD population. And this kind of surveillance has failed to help develop an adequate treatment for NAFLD-related HCC.²⁴ The AASLD recommends regular HCC screening in every patient with liver cirrhosis and Abdominal ultrasound performed every 6-months remains the main recommended examination.

In our present study, only 29% of patients were in the HCC screening program before diagnosis, with ultrasound and alpha-fetoprotein performed every 6 months. HCC screening before diagnosis was not significantly associated with higher cumulative survival in a simple regression Cox with HR = 0.451 (95% CI 0.194 to 1.048), $p = 0.064$ and remained non-significant after adjustment, resulting in HR = 0.742 (95% CI 0.384 to 1.436). A limitation of our study refers to the small sample size of individuals who had performed screening before the

diagnosis of HCC. Although not statistically significant, the authors believe that an efficient surveillance program would help early diagnosis and favor treatments with a curative function such as ablative and surgical therapies and consequently an increase in the OS of this specific NAFLD-HCC group.

Accordingly, in a multicenter Italian study with 756 patients with HCC related either to NAFLD or HCV, 52% of patients with NAFLD-related HCC were not diagnosed on regular surveillance compared to 37% of patients with HCV-related HCC ($p < 0.0001$), resulting in more advanced HCC burden at diagnosis.²⁴ These results highlight the need to focus future research on identifying those patients with NAFLD who require surveillance in order to establish an earlier diagnosis and offer them treatment.

In the majority of patients, HCC diagnosis was made by imaging (85.5%), and computed tomography was the main method (87%). Although biopsy was performed in 13.7% of our patients, there is a growing need to obtain a tissue sample, both for histopathological studies of prognostic interest as well as for molecular studies. Most patients presented 1 nodule (57.3%) at diagnosis, with the largest nodule diameter average of 54.5 mm.

Regarding the tumor staging at diagnosis 40.5% were within Milan Criteria and according to the BCLC System, most of our patients were classified as early stages. The independent factors associated with shorter general survival were BCLC C-D with HR = 7.193 (95% CI 3.662 to 14.129), $p < 0.001$, and the size of the largest nodule > 42 mm with HR = 1.957 (95% CI 1.035 to 3.699), $p = 0.039$.

Based on our data, was observed that patients with NAFLD HCC, were not previously aware of being carriers of chronic liver disease and only one-third of them were in a surveillance program. Even though most of our patients were in early stages at diagnosis (48% were in BCLC 0-A), more than half of them had died (57.3%), in a mean follow-up of 2.17 (± 1.9) years, which allows us to conclude that these patients besides the chronic liver disease had associated other comorbidities, contributing to a worse prognosis.

HCC treatment was performed in 84.7% of patients and 40.5% underwent more than one treatment during the follow-up. Liver transplantation was performed in 16.2% of cases. In the final evaluation (last visit or death), the authors checked the available images by mRECIST and observed that 80.9% of patients had control images: 42% had the progressive disease; 27.5% had complete response; 8.4% had a partial response, and 3% stable disease. The effect of treatment of HCC was strongly associated with longer survival in the univariate analysis with HR = 0.225 (95% CI 0.096 to 0.531), $p < 0.001$. However, in the multiple Cox regression HCC treatment loses its effect resulting in a HR = 0.472 (95% CI 0.188 to 1.185), $p = 0.110$. After treatment, many patients evolved with decompensation of liver function and worsening of the BCLC staging system, which perhaps explains why the treatment lost its effect in the multivariate analysis.

Conclusion

In conclusion, the authors observed that evaluation of the efficacy of screening in our population regarding OS was hampered due to the sample size (29% had screening), which is not different from the literature in this specific population. The vast majority of patients had comorbidities - risk factors for NAFLD (T2DM, hypertension, DLP, overweight), contributing to a worse outcome even were in early/intermediate tumor stages and were submitted to some kind of treatment for HCC. The authors identified as independent factors of worse prognosis the BCLC stages C–D and the size of the largest nodule larger than 42 mm.

There is a growing demand for the search for both serological and tissue biomarkers for histopathological and molecular studies to guide surveillance, diagnosis, and prognosis, as well as prevention targets and specific therapies for the NAFLD HCC group.

Abbreviations

AASLD, American Association for the Study of Liver Diseases; ALT, Alanine Aminotransferase; AST, Aspartate Aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BMI, Body Mass Index; CR, Complete Response; DLP, Dyslipidemia; EASL, European Association for the Study of the Liver; GGT, Gamma Glutamyl Transferase; HR, Hazard Ratio; HBV, Hepatitis B Virus; HCC, Hepatocellular Carcinoma; HCV, Hepatitis C Virus; HDL, High-Density Lipoprotein; INR, International Normalized Ratio; LDL, Low-Density Lipoprotein; MAFLD, Metabolic Dysfunction-Associated Fatty Liver Disease; NAFLD, Non-Alcoholic Fatty Liver Disease; NAFLD-HCC, Non-Alcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma; NASH, Non-alcoholic steatohepatitis; OS, Overall Survival; PR, Partial Response; PD, Progressive Disease; RFA, Radiofrequency Ablation; SD, Stable Disease; TB, Total bilirubin; TACE, Transarterial Chemoembolization; T2DM, Type 2 diabetes mellitus.

Ethics approval and consent to participate

This study was conducted in accordance with the principles expressed in the Declaration of Helsinki. The study protocols were approved by the Hospital das Clínicas of the Faculdade de Medicina da Universidade de São Paulo committee – CAPPesq, n° 1218/17. Informed consent was not necessarily due to being a retrospective study.

Authors' contributions

Alencar RSM: Designed, collected data, wrote, and drafted the manuscript. Oliveira CP, Chagas AL: Designed, co-wrote, and mentored the manuscript. Fonseca LG, Maccali C, Saud LRC, Xerfan MP: Reviewed the manuscript. Stefano JT: Co-wrote and formatting the manuscript. Herman P, Albuquerque LAC, Alves VAF, Carrilho FJ: Reviewed and critically analyzed the version of the manuscript that received final approval.

Funding

Not applicable.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

Not applicable.

References

1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018;**391**(10127):1301–14.
2. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. *Hepatology* 2018;**68**(1):349–60.
3. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018;**67**(1):328–57.
4. Golabi P, Otgonsuren M, de Avila L, Sayiner M, Rafiq N, Younossi ZM. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). *Medicine (Baltimore)* 2018;**97**(13):e0214.
5. Younossi ZM, Stepanova M, Rafiq N, Makhlof H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. *Hepatology* 2011;**53**(6):1874–82.
6. Younossi ZM, Stepanova M, Rafiq N, Henry L, Loomba R, Makhlof H, et al. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. *Hepatol Commun* 2017;**1**(5):421–8.
7. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020;**73**(1):202–9.
8. Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? *J Hepatol* 2018;**68**(2):326–34.
9. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. *J Clin Oncol* 2016;**34**(15):1787–94.
10. Altekruse SF, Devesa SS, Dickie LA, McGlynn KA, Kleiner DE. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. *J Registry Manag* 2011;**38**(4):201–5.
11. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. *Medicine (Baltimore)*. 2017;**96**(9):e5904.
12. Sayiner M, Golabi P, Younossi ZM. Disease Burden of hepatocellular carcinoma: a global perspective. *Dig Dis Sci* 2019;**64**(4):910–7.
13. Sayiner M, Younossi ZM. Identifying patients at risk from nonalcoholic fatty liver-related hepatocellular carcinomas. *Hepat Oncol* 2016;**3**(2):101–3.
14. Hester D, Golabi P, Paik J, Younossi I, Mishra A, Younossi ZM. Among medicare patients with hepatocellular carcinoma, non-alcoholic fatty liver disease is the most common etiology and cause of mortality. *J Clin Gastroenterol* 2020;**54**(5):459–67.
15. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. *J Hepatol* 2019;**70**(1):151–71.
16. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016;**64**(1):73–84.
17. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018;**15**(1):11–20.
18. Kim D, Tournas A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. *Clin Liver Dis* 2018;**22**(1):133–40.
19. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract* 2017;**128**:40–50.
20. Nanditha A, Ma RC, Ramachandran A, Snehalatha C, Chan JC, Chia KS, et al. Diabetes in Asia and the Pacific: Implications for the Global Epidemic. *Diabetes Care* 2016;**39**(3):472–85.
21. Unnikrishnan R, Pradeepa R, Joshi SR, Mohan V. Type 2 Diabetes: Demystifying the Global Epidemic. *Diabetes* 2017;**66**(6):1432–42.
22. Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. *J Hepatocell Carcinoma* 2021;**8**:223–39.
23. Dyson J, Jaques B, Chattopadhyay D, Lochan R, Graham J, Das D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. *J Hepatol* 2014;**60**(1):110–7.
24. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. *Hepatology* 2016;**63**(3):827–38.
25. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. *Clin Gastroenterol Hepatol* 2015;**13**(3):594–601.e1.
26. Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. *BMC Cancer* 2015;**15**:210.
27. Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, et al. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. *QJM* 2017;**110**(2):73–81.
28. Bruix J, Sherman M. AASoL Diseases. Management of hepatocellular carcinoma: an update. *Hepatology* 2011;**53**(3):1020–2.
29. EAftSotLEa easloffice@easlofficeeu, EAftSot Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018;**69**(1):182–236.
30. Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. *J Hepatol* 2020;**72**(2):288–306.
31. Banerjee A, Chitnis UB, Jadhav SL, Bhawalkar JS, Chaudhury S. Hypothesis testing, type I and type II errors. *Ind Psychiatry J* 2009;**18**(2):127–31.
32. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol* 2012;**10**(12):1342–59.e2.
33. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. *Clin Gastroenterol Hepatol* 2009;**7**(2):234–8.
34. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. *JAMA* 2015;**313**(22):2263–73.
35. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. *J Hepatol* 2012;**56**(6):1384–91.
36. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. *Lancet* 2014;**384**(9945):755–65.
37. Fernandes GDS, Campos D, Ballalai A, Palhares R, da Silva MRA, Palhares DMF, et al. Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data. *J Gastrointest Cancer* 2021;**52**(3):952–8.
38. Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. *Front Oncol* 2020;**10**:601710.
39. Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. *J Clin Transl Hepatol* 2020;**8**(1):76–86.